Perspective Therapeutics Inc (CATX) Stock Price, Quote & News

Company Profile

Perspective Therapeutics, Inc., together with its subsidiaries, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. The company discovers, and develop its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a bet...

Industry: Medical Devices

Sector: Healthcare

Phone: 206 676 0900

Website: www.perspectivetherapeutics.com

Address:

2401 Elliott Avenue, Suite 320, Seattle, United States

Ginopepino Jun. 16 at 9:37 PM

$CATX glad I was preparing for this. Doubled up on shares in the $2S though I should have quadrupled.

0 · Reply

markbass2341 Jun. 16 at 9:09 PM

$CATX which means if u were short u had to run and cover your short positions all day

1 · Reply

markbass2341 Jun. 16 at 9:01 PM

$CATX 2.05 million shares traded and a minimum backslide

0 · Reply

morty104 Jun. 16 at 8:24 PM

$CATX nice day. Still pissed til $12

0 · Reply

srod1122 Jun. 16 at 8:20 PM

$CATX now that’s a close with an exclamation point!!

0 · Reply

TonyFish Jun. 16 at 8:19 PM

$CATX Maybe they are finanaly realizing nobody is selling.

0 · Reply

markbass2341 Jun. 16 at 7:45 PM

$CATX Volume 1.72 million

0 · Reply

ITSALock Jun. 16 at 7:42 PM

$CATX Not our typical close, so far :)

0 · Reply

davioncharles Jun. 16 at 7:09 PM

$CATX

0 · Reply

wurzelpiet Jun. 16 at 5:32 PM

$BBAI $CATX $ZIM $QBTS

0 · Reply

Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting

May 12, 2025, 4:36 PM EDT - 5 weeks ago

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results

May 1, 2025, 7:00 AM EDT - 6 weeks ago

Perspective Therapeutics to Participate in Upcoming May Investor Conferences

Apr 23, 2025, 12:25 PM EDT - 7 weeks ago

Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting

Apr 17, 2025, 7:00 AM EDT - 2 months ago

Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results

Apr 11, 2025, 7:00 AM EDT - 2 months ago

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Mar 31, 2025, 7:00 AM EDT - 2 months ago

Perspective Therapeutics to Participate in Upcoming April Investor Conferences

Mar 26, 2025, 4:10 PM EDT - 2 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results

Mar 17, 2025, 7:00 AM EDT - 3 months ago

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Mar 13, 2025, 2:52 PM EDT - 3 months ago

Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst

Feb 26, 2025, 7:00 AM EST - 3 months ago

Perspective Therapeutics to Present at Upcoming March Investor Conferences

Feb 21, 2025, 7:00 AM EST - 4 months ago

Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results

Feb 5, 2025, 7:00 AM EST - 4 months ago

Perspective Therapeutics to Participate in Upcoming February Investor Conferences

Jan 24, 2025, 7:00 AM EST - 5 months ago

Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium

Jan 6, 2025, 8:00 AM EST - 5 months ago

Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer

Dec 23, 2024, 11:13 AM EST - 6 months ago

Bullish On Perspective Therapeutics: Early Successes And Large Oncology TAM

Dec 20, 2024, 4:16 PM EST - 6 months ago

Perspective Therapeutics: Definitely Not Looking Overvalued Now

Nov 27, 2024, 7:00 AM EST - 7 months ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences in December

Nov 21, 2024, 7:15 AM EST - 7 months ago

Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium

Nov 15, 2024, 4:08 PM EST - 7 months ago

Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024

Nov 12, 2024, 4:05 PM EST - 7 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results

Oct 29, 2024, 7:00 AM EDT - 8 months ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences in November

Oct 23, 2024, 7:00 AM EDT - 8 months ago

Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine

Oct 16, 2024, 7:00 AM EDT - 8 months ago

Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey

Oct 11, 2024, 12:05 PM EDT - 8 months ago

Cancer-Focused Perspective Therapeutics Stock Trades Lower After Drug Study Report

Oct 11, 2024, 8:30 AM EDT - 8 months ago

Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research

Oct 10, 2024, 5:14 PM EDT - 8 months ago

Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research

Oct 7, 2024, 7:00 AM EDT - 9 months ago

Perspective Therapeutics to Participate at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit & JonesResearch Virtual Radiopharma Day

Oct 2, 2024, 3:11 PM EDT - 9 months ago

Perspective: VMT01/02 Melanoma Data Coming For Radiotherapeutic Proof-Of-Concept

Oct 2, 2024, 12:10 PM EDT - 9 months ago

Perspective Therapeutics Inc (CATX) Trading 3.4% Higher on Oct 2

Sep 30, 2024, 7:00 AM EDT - 9 months ago

Perspective Therapeutics to Present at the 37th Annual Congress of the European Association of Nuclear Medicine

Sep 5, 2024, 7:00 AM EDT - 10 months ago

Perspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma

Aug 28, 2024, 7:00 AM EDT - 10 months ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences in September

Aug 12, 2024, 4:05 PM EDT - 11 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 2Q 2024 Results

Jul 30, 2024, 7:00 AM EDT - 11 months ago

Perspective Therapeutics to Participate at Upcoming Investor Conferences in August

Jul 22, 2024, 7:00 AM EDT - 11 months ago

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2024 Financial Results

Jun 12, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Announces Inclusion in the Russell 3000® Index

Jun 11, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Announces 1-for-10 Reverse Stock Split

Jun 10, 2024, 4:10 PM EDT - 1 year ago

Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting

May 24, 2024, 8:01 AM EDT - 1 year ago

Perspective Therapeutics Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

May 20, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024

May 15, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results

May 3, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Participate at Upcoming May Investor Conferences

May 2, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial Results

Apr 30, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETs

Perspective Therapeutics to Participate at Upcoming April Investor Conferences

Apr 8, 2024, 8:00 AM EDT - 1 year ago

0 · Reply

markbass2341 Jun. 16 at 9:09 PM

$CATX which means if u were short u had to run and cover your short positions all day

1 · Reply

markbass2341 Jun. 16 at 9:01 PM

$CATX 2.05 million shares traded and a minimum backslide

0 · Reply

morty104 Jun. 16 at 8:24 PM

$CATX nice day. Still pissed til $12

0 · Reply

srod1122 Jun. 16 at 8:20 PM

$CATX now that’s a close with an exclamation point!!

0 · Reply

TonyFish Jun. 16 at 8:19 PM

$CATX Maybe they are finanaly realizing nobody is selling.

0 · Reply

markbass2341 Jun. 16 at 7:45 PM

$CATX Volume 1.72 million

0 · Reply

ITSALock Jun. 16 at 7:42 PM

$CATX Not our typical close, so far :)

0 · Reply

davioncharles Jun. 16 at 7:09 PM

$CATX

0 · Reply

wurzelpiet Jun. 16 at 5:32 PM

$BBAI $CATX $ZIM $QBTS

0 · Reply

Kingtan Jun. 16 at 5:21 PM

$CATX I am out for 20K shares and waiting another chance 😉

0 · Reply

David_M_ Jun. 16 at 5:01 PM

$CATX

0 · Reply

JDinvestments Jun. 16 at 3:23 PM

$CATX it’s coming STRONG BUYOUT 💰💰💰🚀🚀🚀🚀🚀🚀

0 · Reply

JTMN83 Jun. 16 at 3:22 PM

$CATX Up to $3.54! If all goes to plan with this stock we should see some shenanigans and a 3.20-3.30 close right?

0 · Reply

JoshThe3rd Jun. 16 at 3:17 PM

$CATX XBI down yet our unusual buy vol continues.

0 · Reply

John___wick44 Jun. 16 at 2:39 PM

$CATX going back over 8 this year

0 · Reply

MarbleSlapper Jun. 16 at 2:19 PM

$CATX can we close the week above $3.55? What do you think?

1 · Reply

Xanderzzzzzzz Jun. 13 at 9:30 PM

$CATX

1 · Reply

morty104 Jun. 13 at 8:19 PM

$CATX same ol I so Red

0 · Reply

Kingtan Jun. 13 at 7:23 PM

$CATX thx for the discount 😘

0 · Reply

Kingtan Jun. 13 at 6:52 PM

$CATX nice buying opportunity 🚀

0 · Reply

JDinvestments Jun. 13 at 2:58 PM

$CATX big boys manipulating and stealing cheapies before BUYOUT JMHO 💰💰💰🚀🚀🚀🚀🚀🚀

1 · Reply

Market Cap	235.30M
Revenue (ttm)	1.45M
Net Income (ttm)	-79.28M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-5,467.59%
Debt to Equity Ratio	0.01

Volume	2,058,868
Avg Vol	1,065,930
Day's Range	N/A - N/A
Shares Out	74.23M
Stochastic %K	58%
Beta	1.09
Analysts	Strong Sell
Price Target	$12.54